Supernus Pharmaceuticals (SUPN) Liabilities and Shareholders Equity (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $1.5 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.5 billion, up 11.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 billion (up 7.1% YoY), and the FY2025 annual result was $1.5 billion, up 6.18% from the prior year.
• Liabilities and Shareholders Equity improved to $1.5 billion in Q1 2026 per SUPN's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.8 billion in Q1 2023 and troughed at $1.3 billion in Q4 2023.
• A 5-year average of $1.5 billion and a median of $1.4 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity slipped 27.22% in 2024, then increased 11.39% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.7 billion in 2022, then fell by 24.95% to $1.3 billion in 2023, then increased by 7.08% to $1.4 billion in 2024, then climbed by 6.18% to $1.5 billion in 2025, then climbed by 3.31% to $1.5 billion in 2026.
• Business Quant data shows SUPN's Liabilities and Shareholders Equity at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.